Scholarlink

<p>High-grade gliomas (HGG) are a neuro-oncology challenge due to their aggressive nature,with conventional therapies like radiation and chemotherapy often yielding limited success. Cesium-131 (Cs-131) brachytherapy is a promising adjunct due to its short half-life (9.7&#xa0;days) and high energy, enabling targeted radiation delivery with less exposure. GammaTile (GT Medical Technologies) uses Cs-131 seeds in a bioresorbable collagen matrix, enabling immediate post-surgical radiation while safeguarding healthy tissue. Therefore, this study aims to evaluate the current evidence of using Gammatile in HGG. We performed a systematic review and single-arm meta-analysis. PubMed, Web of Science, Scopus, and Embase were searched for eligible trials. A random-effects model was used to calculate the Proportions and Means, with 95% confidence intervals (CIs) and a significance level of 5%. Statistical analyses were conducted with RStudio 4.3. Twelve studies included 110 patients, 57 male (51.8%), with a mean age of 50.2&#xa0;years and a follow-up of 29.47&#xa0;months. Four endpoints were analyzed: Mortality (Proportion 6%; 95% CI 2% to 15%; I<sup>2</sup> = 0%); Recurrence (Proportion 100%; 95% CI 11% to 100%; I<sup>2</sup> = 0%); Overall Survival (OS) (Mean 27.30&#xa0;months; 95% CI 17.34 to 42.96; I<sup>2</sup> = 63.9%); Progression-Free Survival (PFS) (Mean 8.81&#xa0;months; 95% CI 7.43–10.43; I<sup>2</sup> = 0%). GammaTile shows promising outcomes for HGG, with mean OS of 27.30&#xa0;months, and PFS of 8.81&#xa0;months. Despite the 100% recurrence rate, the 6% mortality rate suggests contribution to prolonging patient survival.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cesium 131 seeds for high-grade gliomas: a systematic review and meta-analysis of gammatile as a brachytherapy innovation

  • 期刊论文

  • 发表日期：

    2025年3月17日

查看全文
  • Lucca B. Palavani,
  • Marcio Yuri Ferreira,
  • Maria Antonia Oliveira Machado Pereira,
  • Lidia Cheidde,
  • Gustavo de Oliveira Almeida,
  • Laura Cheidde,
  • Pedro Paulo Ladeira Júnior,
  • Vinicius Gonçalves Gomes Pereira,
  • Raphael Bertani,
  • Wellingson Paiva

摘要

High-grade gliomas (HGG) are a neuro-oncology challenge due to their aggressive nature,with conventional therapies like radiation and chemotherapy often yielding limited success. Cesium-131 (Cs-131) brachytherapy is a promising adjunct due to its short half-life (9.7 days) and high energy, enabling targeted radiation delivery with less exposure. GammaTile (GT Medical Technologies) uses Cs-131 seeds in a bioresorbable collagen matrix, enabling immediate post-surgical radiation while safeguarding healthy tissue. Therefore, this study aims to evaluate the current evidence of using Gammatile in HGG. We performed a systematic review and single-arm meta-analysis. PubMed, Web of Science, Scopus, and Embase were searched for eligible trials. A random-effects model was used to calculate the Proportions and Means, with 95% confidence intervals (CIs) and a significance level of 5%. Statistical analyses were conducted with RStudio 4.3. Twelve studies included 110 patients, 57 male (51.8%), with a mean age of 50.2 years and a follow-up of 29.47 months. Four endpoints were analyzed: Mortality (Proportion 6%; 95% CI 2% to 15%; I2 = 0%); Recurrence (Proportion 100%; 95% CI 11% to 100%; I2 = 0%); Overall Survival (OS) (Mean 27.30 months; 95% CI 17.34 to 42.96; I2 = 63.9%); Progression-Free Survival (PFS) (Mean 8.81 months; 95% CI 7.43–10.43; I2 = 0%). GammaTile shows promising outcomes for HGG, with mean OS of 27.30 months, and PFS of 8.81 months. Despite the 100% recurrence rate, the 6% mortality rate suggests contribution to prolonging patient survival.